Welcome to our dedicated page for Vera Therapeutics news (Ticker: VERA), a resource for investors and traders seeking the latest updates and insights on Vera Therapeutics stock.
Vera Therapeutics, Inc. (VERA) is a clinical-stage biotechnology company pioneering targeted therapies for autoimmune and inflammatory diseases. This page provides investors and stakeholders with timely updates on clinical developments, regulatory milestones, and corporate announcements.
Access Vera Therapeutics' latest press releases, including progress reports on atacicept for IgA nephropathy (IgAN) and lupus nephritis, updates on its MAU868 antibody program, and strategic partnerships. Our curated news feed ensures you stay informed about pivotal Phase 3 trial results, FDA communications, and financial disclosures that may impact investment decisions.
Key coverage areas include B cell modulation research, clinical trial design innovations, and collaborations with leading medical institutions. Bookmark this page for direct access to primary source materials and analysis-free reporting on Vera's scientific advancements in immunological therapeutics.
Vera Therapeutics announced that the FDA has granted Breakthrough Therapy Designation to its drug atacicept for the treatment of Immunoglobulin A Nephropathy (IgAN). This decision is based on data from a Phase 2b ORIGIN trial, showing atacicept's potential to significantly improve kidney function as measured by eGFR over existing treatments. The company plans to release long-term results from this trial later in 2024 and expects Phase 3 trial results in the first half of 2025, which will support its regulatory approval submission.
Vera Therapeutics announced positive results from its Phase 2b ORIGIN trial of atacicept in treating IgA nephropathy (IgAN) at the 61st European Renal Association Congress. Over 72 weeks, atacicept showed stable kidney function, rapid, and sustained improvements in hematuria compared to placebo. The study revealed a 91% retention rate, enhancing the drug's safety profile. Additionally, atacicept led to significant reductions in Gd-IgA1, hematuria, and UPCR in participants. Vera aims to present 96-week data in Q4 2024 and expects Phase 3 enrollment completion by Q3 2024, with primary endpoint data by H1 2025.
Vera Therapeutics, a biotechnology company, shared positive 72-week data from its Phase 2b ORIGIN clinical trial for IgAN. They reported no kidney function loss with atacicept treatment. They anticipate Phase 3 ORIGIN 3 trial results in 2025. The company completed a $287.5 million financing, strengthening its financial position.
Vera Therapeutics, Inc. (Nasdaq: VERA) granted inducement awards to new employees under its 2024 Inducement Plan. The awards include non-qualified stock options and restricted stock units. The stock options have exercise prices based on Vera's closing trading prices on specific dates. The awards vest over four years, contingent on the employees' continued service with the company. These awards were approved as inducements under Nasdaq Listing Rule 5635(c)(4).
FAQ
What is the current stock price of Vera Therapeutics (VERA)?
What is the market cap of Vera Therapeutics (VERA)?
